Abstract 624P
Background
Most cancer immunotherapy research focuses on gene-level expression, often bypassing the key role of alternative splicing in producing various isoform transcripts. Alternative splicing contributes significantly to tumor heterogeneity, progression, and therapy response1-3. Understanding these dynamics is paramount for advancing personalized treatment strategies.
Methods
1. Data Integration - Integrated multi-omics data from diverse tumor types. - Focused on immune cells within the tumor microenvironment. 2. Sample collection - Gathered data from both pre- and post-immunotherapy treated patients. - Included clinical response details for comprehensive insights. 3. Isoform analysis - Constructed a single-cell isoform atlas capturing the landscape of alternative splicing events and isoform expression profiles across a vast array of cancers. - Investigated patterns of isoform diversity/plasticity: - Within and between different cancer types. - Between pre- and post-treatment scenarios. - Among responders vs. non-responders.
Results
Pan-cancer isoform signatures - For each cancer type and at the pan-cancer level, the isoform patterns of immune cell types linked with oncogenic processes between (i) healthy and cancer; (ii) pre- and post-treatment; (iii) immunotherapy responders and non-responders.
Conclusions
Our pan-cancer single-cell isoform atlas offers a groundbreaking perspective on isoform dynamics in cancer immune environment, enriching our comprehension of tumor intricacies and bolstering efforts toward precision oncology for individualized patient care.
References: 1. Climente-González, H., Porta-Pardo, E., Godzik, A. & Eyras, E. The Functional Impact of Alternative Splicing in Cancer. Cell Reports 20, 2215-2226 (2017). https://doi.org:https://doi.org/10.1016/j.celrep.2017.08.012.
2. Zhang, Y., Qian, J., Gu, C. & Yang, Y. Alternative splicing and cancer: a systematic review. Signal Transduction and Targeted Therapy 6, 78 (2021). https://doi.org:10.1038/s41392-021-00486-7
3. Bonnal, S. C., López-Oreja, I. & Valcárcel, J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nature Reviews Clinical Oncology 17, 457-474 (2020). https://doi.org:10.1038/s41571-020-0350-x
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Pan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract